DBV Technologies S.A. DBVT
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2012-03-29
DBV Technologies S.A. statistics & valuation
Market cap$834.7M
P / B4.9×
Net margin-2607.3%
Return on equity-87.1%
FCF margin-2159.6%
Return on capital-83.7%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating margin | -2609.2% | -2808.7% | -486.0% | -1994.9% | -1727.6% | -1408.7% | -1162.8% |
| Net margin | -2607.3% | -2744.4% | -462.4% | -1987.5% | -1713.5% | -1415.0% | -1169.5% |
| FCF margin | -2159.6% | -2573.2% | -510.7% | -1164.7% | -1912.3% | -1493.4% | -1046.5% |
| Return on assets | -62.9% | -173.5% | -39.7% | -39.1% | -66.7% | -58.6% | -63.3% |
| Return on equity | -87.1% | -415.8% | -51.9% | -49.5% | -98.5% | -77.6% | -89.0% |
| Debt / equity | — | — | — | — | 0.01× | 0.01× | 0.01× |
| Current ratio | 3.67 | 1.43 | 4.26 | 7.56 | 3.64 | 3.93 | 3.79 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.